| 000 | 01602 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515192143.0 | ||
| 264 | 0 | _c20100602 | |
| 008 | 201006s 0 0 eng d | ||
| 022 | _a1937-335X | ||
| 024 | 7 |
_a10.1089/ten.TEA.2009.0295 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKim, Saejeong | |
| 245 | 0 | 0 |
_aEndothelial progenitor populations in differentiating embryonic stem cells. II. Drug selection and functional characterization. _h[electronic resource] |
| 260 |
_bTissue engineering. Part A _cMar 2010 |
||
| 300 |
_a1065-74 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCattle |
| 650 | 0 | 4 |
_aCell Differentiation _xdrug effects |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 |
_aEmbryonic Stem Cells _xcytology |
| 650 | 0 | 4 |
_aEndothelial Cells _xcytology |
| 650 | 0 | 4 |
_aEpoprostenol _xmetabolism |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 |
_aGreen Fluorescent Proteins _xmetabolism |
| 650 | 0 | 4 |
_aHemostasis _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMicroscopy, Phase-Contrast |
| 650 | 0 | 4 |
_aNeovascularization, Physiologic _xdrug effects |
| 650 | 0 | 4 |
_aPromoter Regions, Genetic _xgenetics |
| 650 | 0 | 4 |
_aPuromycin _xpharmacology |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 |
_aTissue Plasminogen Activator _xmetabolism |
| 700 | 1 | _avon Recum, Horst A | |
| 773 | 0 |
_tTissue engineering. Part A _gvol. 16 _gno. 3 _gp. 1065-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/ten.TEA.2009.0295 _zAvailable from publisher's website |
| 999 |
_c19237078 _d19237078 |
||